Berlin/Geneva, 31 May 2022 — On the eve of BioNTech’s annual shareholder meeting, where the German pharmaceutical corporation is expected to report billions of euros in profits from COVID vaccine sales, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the German government, which supported BioNTech’s vaccine research and development with hundreds of millions of euros in public funding, to push the corporation to urgently transfer mRNA vaccine technology to manufacturers in low- and middle-income countries. MSF has identified over 100 manufacturers in low- and middle-income countries which could produce mRNA vaccines for COVID, other diseases and future pandemics, but this would require sharing the technology and know-how.